The executive session is scheduled for 3:00 p.m. ET, providing a platform for the firm to detail its ongoing clinical strategy. Management will remain on-site throughout the three-day event to conduct private meetings with institutional investors, according to the company announcement released Wednesday.

Actinium currently manages a diverse portfolio, including the development of Iomab-B for bone marrow transplant conditioning and the Actimab-A program for acute myeloid leukemia. With a patent portfolio encompassing roughly 250 assets, the company aims to emphasize its proprietary work in cyclotron-based production of Ac-225 and its collaborative research efforts with the National Cancer Institute.